Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 4:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Reduced Vision Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Brolucizumab vs Aflibercept in Patients With Visual Impairment Due to Diabetic Macular Edema

NCT03917472
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Brolucizumab, Aflibercept
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
74
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 66 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Sep 4, 2026, 4:11 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Validity of at Home Visual Acuity Measurements for Telemedicine During Corona Virus (COVID-19) Pandemic

NCT04391166
View directory record Official record
Conditions
Visual Impairment
Interventions
Non invasive visual acuity testing
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 90 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Sep 4, 2026, 4:11 AM EDT
Recruiting Phase 1Phase 2 Interventional

Valproate for the Treatment of Residual Amblyopia

NCT07226141
View directory record Official record
Conditions
Amblyopia, Amblyopia Unilateral, Amblyopia, Anisometropic, Amblyopia Strabismic
Interventions
Valproate, Placebo, Patch
Drug · Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 17 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 4, 2026, 4:11 AM EDT
Terminated No phase listed Observational

Trial Comparing Ketorolac Tromethamine 0.4% & Prednisolone Acetate 1% in Reducing Post-SLT Anterior Chamber Flare & Cells

NCT00410267
View directory record Official record
Conditions
Postoperative Complications, Inflammation, Glaucoma, Open-Angle
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 95 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 8, 2016 · Synced Sep 4, 2026, 4:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Peripheral Vision Training Study

NCT03141164
View directory record Official record
Conditions
Visual Impairment, Cognitive Change
Interventions
computerized training
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 89 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Sep 4, 2026, 4:11 AM EDT
Enrolling by invitation Not applicable Interventional

Direct vs. Conventional SLT in Open-Angle Glaucoma: A RCT

NCT06925477
View directory record Official record
Conditions
GLAUCOMA 1, OPEN ANGLE, D (Disorder)
Interventions
DSLT treatment for Open-Angle Glaucoma, SLT treatment for Open-Angle Glaucoma
Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Sep 4, 2026, 4:11 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO

NCT07734844
View directory record Official record
Conditions
Diabetic Macular Edema (DME)
Interventions
Tabirafusp tedromer, Aflibercept (2.0 mg)
Drug
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
18 Years and older
Enrollment
910 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
9
States / cities
Glendale, California • Pasadena, California • St. Petersburg, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 4, 2026, 4:11 AM EDT
Completed Not applicable Interventional

Measuring Reading Rehabilitation Outcomes

NCT00125632
View directory record Official record
Conditions
Age Related Maculopathy, Retinal Degeneration
Interventions
Eccentric Viewing Training for Reading
Procedure
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 4, 2009 · Synced Sep 4, 2026, 4:11 AM EDT
Completed Phase 3 Interventional

A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy

NCT06602739
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
REGN5713, REGN5715, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 4, 2026, 4:11 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]

NCT04945772
View directory record Official record
Conditions
Retinitis Pigmentosa, Retinitis, Retinal Diseases, Eye Diseases, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Degeneration
Interventions
Gene Therapy Product-MCO-010, Sham Injection
Biological · Procedure
Lead sponsor
Nanoscope Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Beverly Hills, California • Pensacola, Florida • Fargo, North Dakota + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Sep 4, 2026, 4:11 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Neurodevelopmental Outcomes in Cerebral Visual Impairment

NCT07212010
View directory record Official record
Conditions
Cerebral Visual Impairment
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Months to 72 Months
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2031
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Sep 4, 2026, 4:11 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Refractive Accuracy of "2WIN" and Portable Autorefractors

NCT04249505
View directory record Official record
Conditions
Refractive Error - Myopia Axial, Astigmatism, Accomodation, Visual Impairment, Hyperopia of Both Eyes
Interventions
"2WIN" Photoscreener, "Plusoptix A12", "Retinomax"
Device
Lead sponsor
Alaska Blind Child Discovery
Other
Eligibility
6 Months to 95 Years
Enrollment
708 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Anchorage, Alaska
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Sep 4, 2026, 4:11 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Advanced Spatiomotor Rehabilitation for Navigation in Blindness & Visual Impairment

NCT05377853
View directory record Official record
Conditions
Blindness, Blindness, Acquired, Low Vision, Blindness, Complete
Interventions
Cognitive-Kinesthetic Navigational Training
Behavioral
Lead sponsor
Smith-Kettlewell Eye Research Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Sep 4, 2026, 4:11 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study

NCT02390245
View directory record Official record
Conditions
Glaucoma, Glaucoma Suspect, Diabetic Retinopathy, Ocular Hypertension, Cataract, Branch Retinal Vein Occlusion, Branch Retinal Arterial Occlusion, Central Retinal Vein Occlusion, Central Retinal Artery Occlusion, Epi-retinal Membrane, Macular Degeneration, Drusen, Loss of Vision
Interventions
Free Eye Screenings, Enhanced Intervention, Usual Care
Other
Lead sponsor
Wills Eye
Other
Eligibility
40 Years and older
Enrollment
906 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 21, 2022 · Synced Sep 4, 2026, 4:11 AM EDT
Withdrawn Not applicable Interventional

IOP and Medication Reduction in MIGS Procedures

NCT04202510
View directory record Official record
Conditions
Open Angle Glaucoma, Primary Open Angle Glaucoma, Pigmentary Glaucoma, Pseudoexfoliation Glaucoma in Both Eyes
Interventions
Glaucoma and Cataract Surgery
Procedure
Lead sponsor
Wills Eye
Other
Eligibility
40 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Sep 4, 2026, 4:11 AM EDT
Completed Phase 3 Interventional Results available

Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye

NCT04423718
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
Aflibercept High Dose VEGF Trap-Eye (BAY86-5321), Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)
Drug
Lead sponsor
Bayer
Industry
Eligibility
50 Years and older
Enrollment
1,011 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
57
States / cities
Phoenix, Arizona • Fullerton, California • Mountain View, California + 52 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Sep 4, 2026, 4:11 AM EDT
Recruiting No phase listed Observational

DSLT for Reducing Medication in Glaucoma

NCT07390890
View directory record Official record
Conditions
Primary Open Angle Glaucoma, Ocular Hypertension
Interventions
Voyager DSLT
Device
Lead sponsor
The Eye Institute of West Florida
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Largo, Florida
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 4, 2026, 4:11 AM EDT
Not yet recruiting Not applicable Interventional

DSLT in Normal Tension Glaucoma (NTG) Asian Eyes

NCT07300852
View directory record Official record
Conditions
Normal Tension Glaucoma (NTG), Glaucoma, Open Angle Glaucoma (OAG), Glaucoma, Open Angle
Interventions
Direct Selective Laser Trabeculoplasty (DSLT)
Device
Lead sponsor
Ngoc Nguyen Inc.
Other
Eligibility
20 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
San Jose, California
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Sep 4, 2026, 4:11 AM EDT
Completed Phase 2 Interventional Results available

Low Vision Intervention Trial II (LOVIT II)

NCT00958360
View directory record Official record
Conditions
Central Vision Loss From Macular Diseases
Interventions
Interdisciplinary Low Vision Service, Basic Low Vision Service
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
7
States / cities
Hines, Illinois • Baltimore, Maryland • Cincinnati, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2016 · Synced Sep 4, 2026, 4:11 AM EDT
Completed Phase 3 Interventional

A Double-Masked Comparison of FID 123320 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness

NCT06444529
View directory record Official record
Conditions
Ocular Redness
Interventions
Apraclonidine Hydrochloride Ophthalmic Solution, Vehicle
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
5
States / cities
Glendale, California • Garner, North Carolina • Cranberry Township, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Sep 4, 2026, 4:11 AM EDT
Completed Not applicable Interventional

Low Vision Patients' Preference for Colored Filters and Illumination for Near Reading Determined by the LuxIQ/2

NCT03192722
View directory record Official record
Conditions
Ocular Conditions Resulting in Visual Impairment
Interventions
Colored near reading glasses, Lighting as determined by LuxIQ/2 or OttLite Cobra
Device
Lead sponsor
Nova Southeastern University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Sep 4, 2026, 4:11 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)

NCT04603937
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
KSI-301, Aflibercept, Sham Procedure
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
18 Years and older
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
40
States / cities
Phoenix, Arizona • Beverly Hills, California • Fullerton, California + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Sep 4, 2026, 4:11 AM EDT
Active, not recruiting Not applicable Interventional

The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes

NCT01047735
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Obesity
Interventions
Roux-en-Y Gastric Bypass Surgery, Laparoscopic Adjustable Gastric Banding, Lifestyle Weight Loss Intervention
Procedure · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
25 Years to 55 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 4, 2026, 4:11 AM EDT
Completed Phase 2 Interventional

Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma

NCT01693315
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension, Eye Disease
Interventions
AMA0076, Placebo
Drug
Lead sponsor
Amakem, NV
Industry
Eligibility
30 Years to 85 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
6
States / cities
Artesia, California • Inglewood, California • Petaluma, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2013 · Synced Sep 4, 2026, 4:11 AM EDT